Arrowhead Research | ARWR - Ordinary Share Capital


Arrowhead Research reported $135.7M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Agios Pharmaceuticals USD 58.45M 169K Dec/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 135.7M 2.44M Sep/2025
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Incyte USD 198.46M 2.33M Dec/2025
Ionis Pharmaceuticals USD 161.97M 836K Dec/2025
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
Merck USD 2.49B 15.79M Sep/2025
Moderna USD 391M 2M Sep/2025
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Novartis USD 1.91B 10.64M Dec/2025
Sarepta Therapeutics USD 104.96M 196K Dec/2025
TG Therapeutics USD 155.21M 2.81M Sep/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 0 Dec/2025
Xencor USD 71.87M 529K Dec/2025